Search clinical trials for: AVE8112

Total 12 results

Michael J. Fox Foundation for Parkinson's Research
Sanofi

Terminated

A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

Parkinson's Disease

United States
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors

Solid Tumor

Japan
Sanofi

Completed

AVE8062 in Combination With Platinum-taxane Doublet in Advanced Solid Tumor

Neoplasms

France, Italy, Switzerland
Sanofi

Completed

A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies

Sarcoma

Belgium, Hungary, United States, Brazil, France, India, Italy, Serbia, Spain, United Kingdom
Sanofi

Completed

A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor

Neoplasms, Malignant

Belgium
Sanofi

Completed

Trial of Ombrabulin (AVE8062) in Combination With Taxane and Platinum in Patients With Non-small Cell Lung Cancer (DISRUPT)

Non-small Cell Lung Cancer

France, Romania, Poland, Croatia, Korea, Republic of, Italy, Chile, United States, Australia, Germany, Russian Federation, Serbia, Ukraine
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors

Neoplasms, Malignant

Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors

Advanced Neoplastic Disease
Sanofi

Completed

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Sanofi

Completed

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Neoplasms, Malignant

Japan
Sanofi

Completed

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel (OPSALIN)

Ovarian Cancer Recurrent

Belgium, Russian Federation, Poland, Spain, Czech Republic, United States, France, Germany, Italy, Ukraine
Sanofi

Completed

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Neoplasms, Malignant

France, United Kingdom, Italy

3

Subscribe